Investor Presentaiton

Cardiovascular Camzyos: Phase 3 trial in nHCM underway milvexian Camzyos MYK-224 ODYSSEY H C M Patients with symptomatic nHCM (NYHA Class II or III) Key Inclusion: Diagnosis of HCM per ACC/AHA and ESC guidelines Peak LVOT < 30 mmHg at rest / < 50 mm Hg with provocation NYHA Class II or III Mavacamten Key Exclusion: R • Known infiltrative or storage disorder that mimics nHCM 1:1 H/o unexplained syncope within 6 months prior to screening Placebo • H/o SVT within 6 months prior to screening Assessment of Primary Endpoints at Week 48: • Exercise Capacity (PVO2) PRO (KCCQ) 1. NCT05582395 Ill Bristol Myers Squibb™ Data expected in 2025 Not for Product Promotional Use 122

View entire presentation